Tempest TherapeuticsNASDAQ: TPST

Tempest Therapeutics (NASDAQ: TPST ) stock is heading higher on Thursday after the clinical-stage oncology company announced plans to show off new study data. Tempest Therapeutics will be holding a conference call at 8:30 a.m.

Tempest Therapeutics, Inc. saw promising results in a phase 1b/2 study using TPST-1120 in combination with Tecentriq and Avastin for treating first-line HCC patients, with significant improvements in both confirmed and unconfirmed responses. Updated results from the study are anticipated in 2024. The global market for liver cancer drugs is projected to reach $7.6 billion by 2033.

Remarkably, the stock did not have fundamentally changing news. It did not rocket higher on breaking news that would typically be associated with the whopping gains it experienced.

Shares of Tempest Therapeutics Inc. TPST, -8.54% fell more than 8% Friday to conclude a dramatic week in which the stock clocked a one-day gain of nearly 4,000%.

Shares of microcap oncology company Tempest Therapeutics Inc. TPST, -55.06% dropped more than 50% Thursday as investors took a breath after the stock's roughly 40-fold gain on Wednesday.

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.

Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ: TPST ). This little-known clinical-stage oncology company has gone from trading at 30 cents per share 24 hours ago to its current share price of $6.40.

Tempest Therapeutics (NASDAQ: TPST ) stock is taking off on Wednesday as the clinical-stage oncology company prepares to release new study results. According to a press release from the company, it intends to release updated study results from a Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab.

Tempest Therapeutics (NASDAQ: TPST ) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the cancer therapies company reported positive results for its TPST-1120 drug candidate in its randomized Phase 1b/2 clinical study.